Facilities

VGXI opens new HQ and manufacturing facility in Texas

24-Oct-2022 By Rachel Arthur

CDMO VGXI has officially opened its new headquarters and manufacturing facility in Conroe, Texas.

Andelyn Biosciences opens GMP manufacturing facility

20-Oct-2022 By Rachel Arthur

US gene therapy CDMO, Andelyn Biosciences, has opened a new GMP clinical and commercial manufacturing facility to support cell and gene therapy (CGT) development and manufacturing.

BioNTech to build mRNA center in Australia

11-Oct-2022 By Rachel Arthur

BioNTech will establish an mRNA research and innovation center in Victoria, alongside clinical scale manufacturing capabilities. Meanwhile, it has also pledged to step up clinical development of oncology therapies in the country.

Orca Bio expands manufacturing capabilities to take cell therapies through to commercialization

13-Sep-2022 By Rachel Arthur

Orca Bio, a biotech developing high-precision cell therapies for the treatment of cancer, genetic blood disorders and autoimmune diseases, will expand its current manufacturing capabilities with the construction of a new 100,000-square-foot commercial...

Biotimize opens fundraising round to build first biological CDMO in Brazil

05-Sep-2022 By Rachel Arthur

Biotimize has announced the opening of a $30m Series A fundraising round: with the investment set to enable Biotimize to build the first biological CDMO in Brazil and to become the first end-to-end biological CDMO in South America.

Applied StemCell expands manufacturing facility to support cell and gene therapies

30-Aug-2022 By Rachel Arthur

Applied StemCell is expanding its cGMP facility to increase its cell banking and cell product manufacturing capacity.

WuXi STA breaks ground on new Delaware manufacturing facility

17-Aug-2022 By BioPharma-Reporter

CRDMO WuXi STA has begun construction of a new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware.

Sartorius to acquire Albumedix for $502m

09-Aug-2022 By Rachel Arthur

Life science group Sartorius will acquire UK recombinant albumin-based solution company Albumedix.

RoslinCT and Lykan Bioscience combine to create advanced cell therapy CDMO

04-Aug-2022 By Rachel Arthur

Edinburgh CDMO RoslinCT and Massachusetts CDMO Lykan Bioscience will combine to create a global advanced therapies CDMO: offering significantly expanded manufacturing capacity.

Thermo Fisher Scientific expands New York cell culture media manufacturing site

04-Aug-2022 By Rachel Arthur

A $76m investment in the facility in Grand Island, New York, will increase capacity to produce raw materials used in manufacture of vaccines and biologic therapies.

Increased demand for aseptic filling sees Cytiva boost manufacturing capacity in Vancouver

28-Jul-2022 By Jane Byrne

This week saw Cytiva open a new 126 200 ft2 (11,724 m2) site in the greater Vancouver area, Canada.

Samsung Biologics on track to open ‘super plant’ in October

28-Jul-2022 By Rachel Arthur

Construction of Samsung Biologics’ Plant 4 is on schedule with operations set to start in October, the company confirmed in its Q2 results this morning.

Bavarian Nordic gets US and EU approval for Denmark fill finish vaccine facility

28-Jul-2022 By Rachel Arthur

Bavarian Nordic A/S has received approvals from the US and EU regulatory authorities to manufacture its Jynneos/Imvanex smallpox and monkeypox vaccine at its fill and finish facility in Denmark.

Astellas to create $70m biotech campus in San Francisco

25-Jul-2022 By Rachel Arthur

Astellas Pharma Inc. will build a biotechnology campus in South San Francisco: providing capabilities to develop cell and gene therapies.

WuXi Biologics to build CRDMO center in Singapore

21-Jul-2022 By Rachel Arthur

CDMO WuXi Biologics will invest $1.4bn in a 10 year investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.

Cytiva investing in additional resins manufacturing operations

18-Jul-2022 By Jane Byrne

Cytiva is investing in additional resins manufacturing operations, with the acquisition of a new facility in Muskegon, Michigan.

Samsung Bio reports progress in reducing Scope 1 and 2 emissions

13-Jul-2022 By Jane Byrne

Samsung Biologics says it is actively working to engage its suppliers to transition to net zero emissions in multiple areas and invest in renewable energy.

Fujifilm to invest $1.6bn and make its Hillerød facility in Denmark the largest end-to-end CDMO in Europe

30-Jun-2022 By Jane Byrne

Fujifilm Corporation is to invest US$1.6bn (€1.4bn) to boost the business of its subsidiary, Fujifilm Diosynth Biotechnologies (FDB), a contract development and manufacturing organization (CDMO).

Croda awarded $75m from US government to expand production of raw materials for mRNA vaccines

30-Jun-2022 By Jane Byrne

UK pharma group, Croda International, has inked a deal with the US government in which it will receive up to US$75m to expand its US manufacturing capacity for lipid systems.

Kite secures third approved cell therapy indication in Europe

28-Jun-2022 By Jane Byrne

The European Commission (EC) has approved Kite’s CAR T-cell therapy, Yescarta, (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.

Spanish CDMO adapts production capabilities, boosts workforce to meet rising viral vector demand

27-Jun-2022 By Jane Byrne

VIVEbiotech has completed the latest expansion phase of its lentiviral vector manufacturing capabilities; the development is aimed at alleviating the viral vector bottleneck for advanced therapies.

US: Merck doubles production capacity of ADC components

23-Jun-2022 By Jane Byrne

Merck has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of its facility in Verona, Wisconsin, US.

BIO International: US CDMO looks to plug critical cell therapy manufacturing capacity shortage

16-Jun-2022 By Jane Byrne

The BIO International Convention in San Diego this week heard the US-based Center for Breakthrough Medicines (CBM) is to speed up plans to build what it calls the largest cell therapy manufacturing operation worldwide.

bio 2022

ten23 adds manufacturing building in rapid build out

14-Jun-2022 By Ben Hargreaves

The newly launched CDMO plans to set up two new manufacturing lines, after expanding into a 5,000-square-meter manufacturing facility.

Regenxbio: Bringing our manufacturing in-house allows us full control of the process

13-Jun-2022 By Jane Byrne

Regenxbio has officially opened its new gene therapy manufacturing facility.

Evonik announces $220m lipid production facility for mRNA-based therapies

06-Jun-2022 By Rachel Arthur

Evonik will build a production facility for pharmaceutical lipids in Indiana: with the new site ‘positioning the group for future growth in novel mRNA-based therapies beyond COVID-19 vaccines’.

CordenPharma increases xRNA-based capabilities with LNP formulation investment in Italy

06-Jun-2022 By Rachel Arthur

CDMO CordenPharma has increased its xRNA capabilities at its sterile injectable facility in Caponago, Italy: with a €10m ($10.7m) investment in new Lipid Nanoparticle (LNP) formulation, development and production areas.

Lilly invests $2.1bn in new Indiana manufacturing sites

31-May-2022 By Rachel Arthur

Eli Lilly and Company plans to expand its manufacturing footprint in Indiana by investing $2.1bn in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.

Evotec expands cell therapy manufacturing with acquisition

31-May-2022 By Ben Hargreaves

Evotec agrees to acquire Rigenerand, which adds a manufacturing facility capable of producing cell therapies to its infrastructure in Italy.

Merck KGaA launches largest single investment in manufacturing

27-May-2022 By Ben Hargreaves

As part of a wider expansion project, Merck commits to expanding an existing facility and building an entirely new one, as part of its strategy to focus on investment in Ireland.

Hanmi expands offerings with ‘high-tech’ CDMO services

27-May-2022 By Ben Hargreaves

The South Korean company moves to include the raw materials behind mRNA vaccines as part of its CDMO package.

AGC Biologics adds new viral vector suspension capabilities at US cell & gene facility

19-May-2022 By Rachel Arthur

AGC Biologics will add viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its commercial-grade campus in Longmont, Colorado.

Novartis looks to work more strategically as CDMO

16-May-2022 By Jane Byrne

Novartis has recently set up a new contract development and manufacturing unit called Global Biotech Co-operations (GBTC).

Gerresheimer ramps up glass and plastic production capacities in India

16-May-2022 By Jane Byrne

Gerresheimer has enhanced its manufacturing capabilities in India, in an effort to ensure consistent, local supply for pharma and healthcare operations.

Matica Bio opens new Texas cell and gene therapy facility

06-May-2022 By Rachel Arthur

CDMO Matica Bio has opened a new 45,000-square-foot facility dedicated to the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.

Scorpion Biological Services to create new Kansas biomanufacturing facility

26-Apr-2022 By Rachel Arthur

CDMO Scorpion Biological Services will build a new biodefense-focused large molecule and biologics biomanufacturing facility in Manhattan, Kansas.

Catalent acquires New Jersey cell therapy development and manufacturing facility

25-Apr-2022 By Rachel Arthur

Catalent has acquired a commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, from Erytech Pharma for $44.5m.

Catalent to invest $350m to expand US drug substance and product manufacturing site

22-Apr-2022 By Jane Byrne

Catalent has announced a multi-year $350m investment at its facility in Bloomington, Indiana, to expand biologics drug substance and drug product manufacturing capabilities.

Asahi Kasei Medical acquires US biologics CDMO business

21-Apr-2022 By Jane Byrne

Bionova Scientific, a US biologics CDMO, is to be acquired by the US arm of Asahi Kasei Medical, part of the Asahi Kasei Group, owned by Tokyo based Asahi Kasei Corporation.

Kite’s Maryland CAR T-cell therapy site gets FDA go-ahead

19-Apr-2022 By Jane Byrne

Kite, a Gilead company, says the US Food and Drug Administration (FDA) has approved commercial production at the company's new CAR T-cell therapy manufacturing facility in Frederick, Maryland.

High Purity New England launches new manufacturing facility

18-Apr-2022 By Rachel Arthur

High Purity New England (HPNE), a supplier of single-use solutions for the biopharmaceutical industry, has launched its third facility.

US and South Korean microbiome CDMO partnership to build US facility

12-Apr-2022 By Jane Byrne

List Bio, together with List Labs, is set to build a new US$125m plant in Indiana, offering end-to-end manufacturing for early-stage development through to commercial production of new microbiome therapeutics.

Germany locks in vaccine manufacturing capacity with GSK, CureVac, BioNTech and others

12-Apr-2022 By Rachel Arthur

Germany has made a series of contracts with vaccine manufacturers to reserve mRNA manufacturing capacity in the country as part of its pandemic preparedness plans.

Catalent buys UK vaccine manufacturing centre

07-Apr-2022 By Rachel Arthur

US company Catalent is acquiring the UK’s Vaccine Manufacturing and Innovation Centre in Harwell: a facility which had been planned to support COVID-19 and wider vaccine production and which is still under construction.

Novartis’ North Carolina gene therapy manufacturing site gets FDA approval

06-Apr-2022 By Rachel Arthur

The US Food and Drug Administration (FDA) has granted commercial licensure approval for Novartis’ Durham, N.C. site, a multi-product gene therapy manufacturing facility, which will start producing Zolgensma immediately.

Milestone approval for Kite CAR-T cell therapy

04-Apr-2022 By Jane Byrne

The US FDA has approved Yescarta, Kite's CAR-T cell therapy, for initial treatment in adults with large B-cell lymphoma (LBCL) that is refractory to one prior therapy or that relapses within 12 months of first-line chemoimmunotherapy.

Vetter and Rentschler progress joint CDMO collaborative work

04-Apr-2022 By Jane Byrne

Vetter and Rentschler Biopharma are looking to boost the awareness and benefits of their strategic CDMO alliance.

Abzena secures $65m to expand production capacity, mammalian biologics site set to come online

31-Mar-2022 By Jane Byrne

Abzena, a global CDMO specializing in the integrated development and manufacture of complex biologics and bioconjugates, has secured $65M in new funding.

ThermoGenesis launches automated cell therapy CDMO

31-Mar-2022 By Ben Hargreaves

The company will also begin work on creating a cGMP manufacturing facility in Sacramento, California, to house its CDMO division.

From textiles to therapies: North Carolina’s journey to a booming biotech hub

29-Mar-2022 By Rachel Arthur

While skills shortages present one of the main challenges to the biopharma industry, North Carolina believes its investments in the life science ecosystem have given it a ‘multiple decade jumpstart’ in building a successful biopharma hub for both manufacturing...